ArticleSensors (Basel, Switzerland)2021
Feasibility and First Results of Heart Failure Monitoring Using the Wearable Cardioverter-Defibrillator in Newly Diagnosed Heart Failure with Reduced Ejection Fraction.
Article in Sensors (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 12 citations in OpenAlex.
- Clinical Utility of the TRENDS Remote Monitoring Function Integrated into a Wearable Cardioverter-Defibrillator.Sensors (Basel, Switzerland) · 2026Article
- Variabiliy in Prescribing Patterns of Wearable Cardiac Defibrillators: Current Data, Guidelines, Challenges, and Controversies.Current cardiology reports · 2025Review
- Ultra-short-term heart rate variability using a photoplethysmography-based smartphone application: a TeleCheck-AF subanalysis.European heart journal. Digital health · 2025Article
- [Remote monitoring for patients with cardiac implantable electronic devices and heart failure].Herzschrittmachertherapie & Elektrophysiologie · 2025Review
- State of the art of mobile health technologies use in clinical arrhythmia care.Communications medicine · 2024Review
- A scoping review on advancements in noninvasive wearable technology for heart failure management.NPJ digital medicine · 2024Article
- The Role of the Wearable Defibrillator in Heart Failure.Current heart failure reports · 2024Review
- Dynamic changes in nocturnal heart rate predict short-term cardiovascular events in patients using the wearable cardioverter-defibrillator: from the WEARIT-France cohort study.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2023Article
- ANMCO position paper: guide to the appropriate use of the wearable cardioverter defibrillator in clinical practice for patients at high transient risk of sudden cardiac death.European heart journal supplements : journal of the European Society of Cardiology · 2023Article
- Assessing physical activity with the wearable cardioverter defibrillator in patients with newly diagnosed heart failure.Frontiers in cardiovascular medicine · 2023Article
- Usage of the wearable cardioverter-defibrillator during pregnancy.International journal of cardiology. Heart & vasculature · 2022Article
- Multiparameter Monitoring with a Wearable Cardioverter Defibrillator.Sensors (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The wearable cardioverter-defibrillator (WCD) is used in patients with newly diagnosed heart failure and reduced ejection fraction (HFrEF). In addition to arrhythmic events, the WCD provides near-continuous telemetric heart failure monitoring. The purpose of this study was to evaluate the clinical relevance of additionally recorded parameters, such as heart rate or step count. We included patients with newly diagnosed HFrEF prescribed with a WCD. Via the WCD, step count and heart rate were acquired, and an approximate for heart rate variability (HRV5) was calculated. Multivariate analysis was performed to analyze predictors for an improvement in left ventricular ejection fraction (LVEF). Two hundred and seventy-six patients (31.9% female) were included. Mean LVEF was 25.3 ± 8.5%. Between the first and last seven days of usage, median heart rate fell significantly (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.